Basurto SD, Lorenzana-Jiménez M, Magos GGA

Idioma: Español
Referencias bibliográficas: 32
Paginas: 157-162
Archivo PDF: 93.92 Kb.

FRAGMENTO

En la República Mexicana la diabetes mellitus es la primera causa de mortalidad general. El tratamiento farmacológico de este síndrome metabólico es de por vida, y pretende controlar las manifestaciones clínicas y prevenir complicaciones. Desafortunadamente, para muchos pacientes no se logra y además, los fármacos utilizados son costosos y presentan efectos adversos importantes. Probablemente ante la necesidad de abatir los costos y tener mejores recursos terapéuticos, la población mexicana tanto de zonas rurales como urbanas, utiliza el nopal como tratamiento alternativo o combinado con fármacos, para la diabetes mellitus tipo 2.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Coronado GD, Thompson B, Tejeda S, Godina R. Attitudes and beliefs among Mexican Americans about type 2 diabetes. J Health Care Poor Underserved 2004; 15(4): 576-88.

2. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26(4): 1277-94.

3. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc 2002; 42(2): 217-26.

4. Ibañez-Camacho R, Roman R. Hypoglycemic effect of Opuntia cactus. Arch Invest Med 1979; 10: 223-30.

5. Satta MA, Sisini A. Glucose-6-phosphatase and fructose-1, 6-diphosphatase activity in Opuntia ficus indica. Bol Soc Ital Biol Sper 1964; 40: 1109-10.

6. Sisini A. On glucose-6-phosphate isomerase in Opuntia ficus indica. Bol Soc Ital Biol Sper 1969; 45: 794-6.

7. Ibañez-Camacho R, Meckes-Lozoya M. Effect of a semipurified product obtained from Opuntia streptacantha L. (a cactus) on glycemia and triglyceridemia of rabbit. Arch Invest Med 1983; 14(4): 437-43.

8. Ibañez-Camacho R, Meckes-Lozoya M, Mellado-Campos V. The hypoglucemic effect of Opuntia streptacantha studied in different animal experimental models. J Ethnopharmacol 19837; (2): 175-81.

9. Meckes-Lozoya M, Ibañez-Camacho R. Hypoglucaemic activity of Opuntia streptacantha throughout its annual cycle. Am J Chin Med 1989; 17: 221-4.

10. Roman-Ramos R, Flores-Saenz JL, Alarcón-Aguilar FJ. Anti-hyperglycemic effect of some edible plants. J Ethnopharmacol 1995; 48: 25-32.

11. Trejo-González A et al. A purified extract from prickly pear cactus (Opuntia fuliginosa) controls experimentally induced diabetes in rats. J Ethnopharmacol 1996; 55: 27-33.

12. Bwititi P, Musabayane CT, Nhachi CF. Effects of Opuntia megacantha on blood glucose and kidney function in streptozotocin diabetic rats. J Ethnopharmacol 2000; 69(3): 247-52.

13. Cardenas MML, Serna SSO, Velazco GJ. Effect of raw and cooked nopal (Opuntia ficus indica) ingestion on growth and profile of total cholesterol, lipoproteins, and blood glucose in rats. Arch Latinoam Nutr 1998; 48: 316-23.

14. Laurenz JC, Collier CC, Kuti JO. Hypoglycaemic effect of Opuntia lindheimeri Englem in a diabetic pig model. Phytother Res 2003; 17: 26-9.

15. Alarcón-Aguilar FJ et al. Hypoglycemic activity of two polysaccharides isolated from Opuntia ficus-indica and Opuntia streptacantha. Proc West Pharmacol Soc 2003; 46: 139-42.

16. Frati-Munari AC, Fernández-Harp JA, de la Riva H, Ariza-Andraca R, del Carmen Torres M. Effects of nopal (Opuntia sp.) on serum lipids, glycemia and body weight. Arch Invest Med 1983; 14: 117-25.

17. Frati-Munari AC, Fernández-Harp JA, Banales-Ham M, Ariza-Andraca CR. Decreased blood glucose and insulin by nopal (Opuntia sp.). Arch Invest Med 1983; 14: 269-74.

18. Fernández-Harp JA, Frati-Munari AC, Chávez NA, De la Riva PHB, Mares GG. Estudios hormonales en la acción del nopal sobre la prueba de tolerancia a la glucosa informe preliminar. Rev Med IMSS 1984; 22: 387-390.

19. Frati-Munari AC, Yever-Garces A, Islas-Andrade S, Ariza-Andraca CR, Chavez-Negrete A. Studies on the mechanism of “hypoglycemic” effect of nopal (Opuntia sp.). Arch Invest Med 1987; 18: 7-12.

20. Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care 1988; 11: 63-6.

21. Frati-Munari AC, Del Valle-Martínez LM, Ariza-Andraca CR, Islas-Andrade S, Chávez-Negrete A. Hypoglycemic action of different doses of nopal (Opuntia streptacantha Lemaire) in patients with type II diabetes mellitus. Arch Invest Med 1989; 20: 197-201.

22. Frati-Munari AC, De León C, Ariza ACR, Banales HMB, López LR, Lozoya X. Influencia de un extracto deshidratado de nopal (Opuntia streptacantha Lem) en glucemia. Arch Invest Med 1989; 20: 211-216.

23. Frati-Munari AC, Rios Gil U, Ariza-Andraca CR, Islas Andrade S, Lopez Ledesma R. Duration of the hypoglycemic action of Opuntia streptacantha Lem. Arch Invest Med 1989; 20: 297-300.

24. Frati-Munari AC, Altamirano-Bustamante E, Rodriguez-Barcenas N, Ariza-Andraca R, Lopez-Ledesma R. Hypoglycemic action of Opuntia streptacantha Lemaire: study using raw extracts. Arch Invest Med 1989; 20: 321-5.

25. Frati-Munari AC, Licona QR, Araiza ACR, López LR, Chávez NA. Acción de Opuntia streptacantha en individuos sanos con hiperglucemia inducida. Arch Invest Med 1990; 21: 99-102.

26. Frati AC et al. Influence of nopal intake upon fasting glycemia in type II diabetics and healthy subjects. Arch Inv Med 1991; 22: 51-6.

27. Frati AC, Xilotl DN, Altamirano P, Ariza R, Lopez-Ledesma R. The effect of two sequential doses of Opuntia streptacantha upon glycemia. Arch Inv Med 1991; 22: 333-6.

28. Frati MAC, Vera LO, Ariza ACR. Evaluation of nopal capsules in diabetes mellitus. Gac Med Mex 1992; 128: 431-6.

29. Wolfram R, Budinsky A, Efthimiou Y, Stomatopoulos J, Oguogho A. Sinzinger H. Daily prickly pear consumption improves platelet function. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 61-6.

30. Hermans MP, Buysschaert M. Pharmacological treatment of type 2 diabetes. Acta Clin Belg 2004; 59: 59-66.

31. Verges B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr Med Res Opin 2005; 1: S29-40.

32. Ylönen K et al. Associations of dietary fiber with glucose metabolism in nondiabetic relatives of subjects with type 2 diabetes. Diabetes Care 2003; 26: 1979-85.